Related references
Note: Only part of the references are listed.Pharmacodynamic Model of Sodium-Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology
Tristan S. Maurer et al.
AAPS JOURNAL (2011)
Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2
Charles S. Hummel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Diminished glucagon suppression after β-cell reduction is due to impaired α-cell function rather than an expansion of α-cell mass
Juris J. Meier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)
TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity
K. Yamamoto et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Fanconi-Bickel syndrome in a 3-year-old Indian boy with a novel mutation in the GLUT2 gene
Arun Gopalakrishnan et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2011)
Early Growth Retardation and Insulin Resistance in JAZF1 KO Mice
Hui-Young Lee et al.
DIABETES (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes
Stephen S. Johnston et al.
DIABETES CARE (2011)
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
S. Kasichayanula et al.
DIABETES OBESITY & METABOLISM (2011)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
HbA(1c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study
R. Borg et al.
DIABETOLOGIA (2011)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Discovery of Novel N-β-D-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes
Chun-Hsu Yao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
The Sweet Pee Model for Sglt2 Mutation
Joseph P. Ly et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
SGLT2 inhibitors: molecuar design and potential differences in effect
Masayuki Isaji
KIDNEY INTERNATIONAL (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
Michael J. Jurczak et al.
DIABETES (2011)
Type 2 diabetes as an inflammatory disease
Marc Y. Donath et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Functional expression of SGLTs in rat brain
Amy S. Yu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2010)
Emerging treatment options for type 2 diabetes
Milan K. Piya et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Glucose regulation of beta-cell stress in type 2 diabetes
G. Leibowitz et al.
DIABETES OBESITY & METABOLISM (2010)
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
L. Zhang et al.
DIABETES OBESITY & METABOLISM (2010)
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
M. Obermeier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Multiple-Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double-Blind Study
Elizabeth K. Hussey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Discovery of Canagliflozin, a Novel C-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Sumihiro Nomura et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy
Sanjay K. Banerjee et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Neuronal regulation of homeostasis by nutrient sensing
Tony K. T. Lam
NATURE MEDICINE (2010)
Role of Reactive Oxygen Species in the Progression of Type 2 Diabetes and Atherosclerosis
Hideaki Kaneto et al.
MEDIATORS OF INFLAMMATION (2010)
Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients
Dirk von Lewinski et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Facilitative glucose transporter 9, a unique hexose and urate transporter
Manuel Doblado et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P. H. Wilding et al.
DIABETES CARE (2009)
Glucose regulation of islet stress responses and β-cell failure in type 2 diabetes
J. C. Jonas et al.
DIABETES OBESITY & METABOLISM (2009)
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
Bruce A. Ellsworth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
Wei Meng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
Yoshikazu Fujimori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion
Joaquim Calado et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Regulation of renal glucose transporters during severe inflammation
Christoph Schmidt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Active sugar transport in health and disease
E. M. Wright et al.
JOURNAL OF INTERNAL MEDICINE (2007)
Familial renal glucosuria:: SLC5A2 mutation analysis and evidence of salt-wasting
J Calado et al.
KIDNEY INTERNATIONAL (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion
G Vervoort et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria
J Calado et al.
HUMAN GENETICS (2004)
High glucose levels down-regulate glucose transporter expression that correlates with increased oxidative stress in placental trophoblast cells in vitro
H Li et al.
JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION (2004)
Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension
R Bautista et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2004)
HNF1α controls renal glucose reabsorption in mouse and man
M Pontoglio et al.
EMBO REPORTS (2000)
Share Paper
